Le diagnostic repose sur des tests sanguins pour détecter les anticorps ou l'ARN viral.
DengueDiagnostic médical
#2
Quels tests pour le paludisme au Vietnam ?
Un frottis sanguin ou un test de diagnostic rapide sont utilisés pour le paludisme.
PaludismeTests de diagnostic
#3
Comment identifier la tuberculose ?
La tuberculose est diagnostiquée par des tests cutanés, des radiographies et des cultures.
TuberculoseDiagnostic médical
#4
Quels signes pour le choléra ?
Le choléra se diagnostique par des selles liquides et des tests de laboratoire.
CholéraDiagnostic médical
#5
Comment détecter une infection à VIH ?
Des tests sanguins spécifiques détectent les anticorps ou l'ARN du VIH.
VIHDiagnostic médical
Symptômes
5
#1
Quels symptômes de la dengue ?
Fièvre, douleurs articulaires, éruptions cutanées et fatigue sont fréquents.
DengueSymptômes
#2
Quels signes du paludisme ?
Fièvre, frissons, sueurs, maux de tête et douleurs musculaires sont typiques.
PaludismeSymptômes
#3
Quels symptômes de la tuberculose ?
Toux persistante, perte de poids, sueurs nocturnes et fatigue sont courants.
TuberculoseSymptômes
#4
Quels signes du choléra ?
Diarrhée aqueuse sévère, vomissements et déshydratation rapide sont caractéristiques.
CholéraSymptômes
#5
Quels symptômes d'une infection à VIH ?
Symptômes initiaux incluent fièvre, fatigue, éruptions cutanées et ganglions enflés.
VIHSymptômes
Prévention
5
#1
Comment prévenir la dengue ?
Éliminer les eaux stagnantes et utiliser des répulsifs contre les moustiques.
DenguePrévention
#2
Quelles mesures pour prévenir le paludisme ?
Utiliser des moustiquaires, des insecticides et prendre des médicaments préventifs.
PaludismePrévention
#3
Comment prévenir la tuberculose ?
Vaccination BCG et dépistage des cas contacts sont essentiels pour la prévention.
TuberculosePrévention
#4
Quelles précautions contre le choléra ?
Boire de l'eau potable, se laver les mains et consommer des aliments cuits.
CholéraPrévention
#5
Comment prévenir le VIH ?
Utiliser des préservatifs et se faire dépister régulièrement pour prévenir le VIH.
VIHPrévention
Traitements
5
#1
Quel traitement pour la dengue ?
Le traitement est symptomatique, avec des analgésiques et une hydratation adéquate.
DengueTraitement
#2
Comment traiter le paludisme ?
Des médicaments antipaludiques comme l'artémisinine sont utilisés pour traiter le paludisme.
PaludismeTraitement
#3
Quel traitement pour la tuberculose ?
La tuberculose nécessite un traitement antibiotique prolongé, souvent sur six mois.
TuberculoseTraitement
#4
Comment traiter le choléra ?
Le choléra est traité par réhydratation orale ou intraveineuse et antibiotiques si nécessaire.
CholéraTraitement
#5
Quel traitement pour le VIH ?
Le VIH est traité par des antirétroviraux pour contrôler la charge virale.
VIHTraitement
Complications
5
#1
Quelles complications de la dengue ?
Les complications incluent la dengue sévère, le choc et des hémorragies.
DengueComplications
#2
Quelles complications du paludisme ?
Le paludisme peut entraîner des anémies, des convulsions et des défaillances organiques.
PaludismeComplications
#3
Quelles complications de la tuberculose ?
Les complications incluent la dissémination à d'autres organes et la résistance aux médicaments.
TuberculoseComplications
#4
Quelles complications du choléra ?
La déshydratation sévère peut entraîner un choc hypovolémique et la mort.
CholéraComplications
#5
Quelles complications du VIH ?
Le VIH peut mener à des infections opportunistes et à des cancers associés.
VIHComplications
Facteurs de risque
5
#1
Quels facteurs de risque pour la dengue ?
Vivre dans des zones tropicales, exposition aux moustiques et manque d'assainissement.
DengueFacteurs de risque
#2
Quels facteurs de risque pour le paludisme ?
Vivre dans des zones endémiques, absence de protection contre les moustiques.
PaludismeFacteurs de risque
#3
Quels facteurs de risque pour la tuberculose ?
Conditions de vie précaires, immunodépression et contact avec des malades.
TuberculoseFacteurs de risque
#4
Quels facteurs de risque pour le choléra ?
Accès limité à l'eau potable et à l'assainissement, ainsi que la consommation d'aliments contaminés.
CholéraFacteurs de risque
#5
Quels facteurs de risque pour le VIH ?
Relations sexuelles non protégées, partage de seringues et absence de dépistage.
VIHFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vietnam : Questions médicales les plus fréquentes",
"headline": "Vietnam : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vietnam : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-12",
"dateModified": "2025-05-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vietnam"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Asie du Sud-Est",
"url": "https://questionsmedicales.fr/mesh/D001210",
"about": {
"@type": "MedicalCondition",
"name": "Asie du Sud-Est",
"code": {
"@type": "MedicalCode",
"code": "D001210",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.252.145"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vietnam",
"alternateName": "Vietnam",
"code": {
"@type": "MedicalCode",
"code": "D014744",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Pham Quang Thai",
"url": "https://questionsmedicales.fr/author/Pham%20Quang%20Thai",
"affiliation": {
"@type": "Organization",
"name": "National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam; School of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Viet Nam."
}
},
{
"@type": "Person",
"name": "Le Van Tan",
"url": "https://questionsmedicales.fr/author/Le%20Van%20Tan",
"affiliation": {
"@type": "Organization",
"name": "Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam."
}
},
{
"@type": "Person",
"name": "Marc Choisy",
"url": "https://questionsmedicales.fr/author/Marc%20Choisy",
"affiliation": {
"@type": "Organization",
"name": "Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; Centre for Global Health and Tropical Medicine, University of Oxford, UK."
}
},
{
"@type": "Person",
"name": "H Rogier van Doorn",
"url": "https://questionsmedicales.fr/author/H%20Rogier%20van%20Doorn",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "H T Nguyen",
"url": "https://questionsmedicales.fr/author/H%20T%20Nguyen",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36305320",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/00325481.2022.2141499"
}
},
{
"@type": "ScholarlyArticle",
"name": "Relationship of hepatitis C risk to hepatitis C test acceptance among adult patients participating in an ED hepatitis C screening programme.",
"datePublished": "2023-01-02",
"url": "https://questionsmedicales.fr/article/36593093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/emermed-2022-212726"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hepatitis B and C in Children.",
"datePublished": "2022-06-25",
"url": "https://questionsmedicales.fr/article/35868682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cld.2022.03.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hepatitis C in Poland in 2022.",
"datePublished": "2024-08-02",
"url": "https://questionsmedicales.fr/article/39295189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.32394/pe/191941"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mortality in hepatitis C virus-cured vs. hepatitis C virus-uninfected people with HIV.",
"datePublished": "2023-04-05",
"url": "https://questionsmedicales.fr/article/37070541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/QAD.0000000000003569"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Régions géographiques",
"item": "https://questionsmedicales.fr/mesh/D005842"
},
{
"@type": "ListItem",
"position": 3,
"name": "Asie",
"item": "https://questionsmedicales.fr/mesh/D001208"
},
{
"@type": "ListItem",
"position": 4,
"name": "Asie du Sud-Est",
"item": "https://questionsmedicales.fr/mesh/D001210"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vietnam",
"item": "https://questionsmedicales.fr/mesh/D014744"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vietnam - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vietnam",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vietnam",
"description": "Comment diagnostiquer la dengue au Vietnam ?\nQuels tests pour le paludisme au Vietnam ?\nComment identifier la tuberculose ?\nQuels signes pour le choléra ?\nComment détecter une infection à VIH ?",
"url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vietnam",
"description": "Quels symptômes de la dengue ?\nQuels signes du paludisme ?\nQuels symptômes de la tuberculose ?\nQuels signes du choléra ?\nQuels symptômes d'une infection à VIH ?",
"url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vietnam",
"description": "Comment prévenir la dengue ?\nQuelles mesures pour prévenir le paludisme ?\nComment prévenir la tuberculose ?\nQuelles précautions contre le choléra ?\nComment prévenir le VIH ?",
"url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vietnam",
"description": "Quel traitement pour la dengue ?\nComment traiter le paludisme ?\nQuel traitement pour la tuberculose ?\nComment traiter le choléra ?\nQuel traitement pour le VIH ?",
"url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vietnam",
"description": "Quelles complications de la dengue ?\nQuelles complications du paludisme ?\nQuelles complications de la tuberculose ?\nQuelles complications du choléra ?\nQuelles complications du VIH ?",
"url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vietnam",
"description": "Quels facteurs de risque pour la dengue ?\nQuels facteurs de risque pour le paludisme ?\nQuels facteurs de risque pour la tuberculose ?\nQuels facteurs de risque pour le choléra ?\nQuels facteurs de risque pour le VIH ?",
"url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la dengue au Vietnam ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins pour détecter les anticorps ou l'ARN viral."
}
},
{
"@type": "Question",
"name": "Quels tests pour le paludisme au Vietnam ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un frottis sanguin ou un test de diagnostic rapide sont utilisés pour le paludisme."
}
},
{
"@type": "Question",
"name": "Comment identifier la tuberculose ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La tuberculose est diagnostiquée par des tests cutanés, des radiographies et des cultures."
}
},
{
"@type": "Question",
"name": "Quels signes pour le choléra ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choléra se diagnostique par des selles liquides et des tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Comment détecter une infection à VIH ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins spécifiques détectent les anticorps ou l'ARN du VIH."
}
},
{
"@type": "Question",
"name": "Quels symptômes de la dengue ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, douleurs articulaires, éruptions cutanées et fatigue sont fréquents."
}
},
{
"@type": "Question",
"name": "Quels signes du paludisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, sueurs, maux de tête et douleurs musculaires sont typiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes de la tuberculose ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Toux persistante, perte de poids, sueurs nocturnes et fatigue sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes du choléra ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Diarrhée aqueuse sévère, vomissements et déshydratation rapide sont caractéristiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une infection à VIH ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Symptômes initiaux incluent fièvre, fatigue, éruptions cutanées et ganglions enflés."
}
},
{
"@type": "Question",
"name": "Comment prévenir la dengue ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éliminer les eaux stagnantes et utiliser des répulsifs contre les moustiques."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour prévenir le paludisme ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des moustiquaires, des insecticides et prendre des médicaments préventifs."
}
},
{
"@type": "Question",
"name": "Comment prévenir la tuberculose ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vaccination BCG et dépistage des cas contacts sont essentiels pour la prévention."
}
},
{
"@type": "Question",
"name": "Quelles précautions contre le choléra ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Boire de l'eau potable, se laver les mains et consommer des aliments cuits."
}
},
{
"@type": "Question",
"name": "Comment prévenir le VIH ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des préservatifs et se faire dépister régulièrement pour prévenir le VIH."
}
},
{
"@type": "Question",
"name": "Quel traitement pour la dengue ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est symptomatique, avec des analgésiques et une hydratation adéquate."
}
},
{
"@type": "Question",
"name": "Comment traiter le paludisme ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antipaludiques comme l'artémisinine sont utilisés pour traiter le paludisme."
}
},
{
"@type": "Question",
"name": "Quel traitement pour la tuberculose ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La tuberculose nécessite un traitement antibiotique prolongé, souvent sur six mois."
}
},
{
"@type": "Question",
"name": "Comment traiter le choléra ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choléra est traité par réhydratation orale ou intraveineuse et antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Quel traitement pour le VIH ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le VIH est traité par des antirétroviraux pour contrôler la charge virale."
}
},
{
"@type": "Question",
"name": "Quelles complications de la dengue ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la dengue sévère, le choc et des hémorragies."
}
},
{
"@type": "Question",
"name": "Quelles complications du paludisme ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le paludisme peut entraîner des anémies, des convulsions et des défaillances organiques."
}
},
{
"@type": "Question",
"name": "Quelles complications de la tuberculose ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la dissémination à d'autres organes et la résistance aux médicaments."
}
},
{
"@type": "Question",
"name": "Quelles complications du choléra ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation sévère peut entraîner un choc hypovolémique et la mort."
}
},
{
"@type": "Question",
"name": "Quelles complications du VIH ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le VIH peut mener à des infections opportunistes et à des cancers associés."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour la dengue ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vivre dans des zones tropicales, exposition aux moustiques et manque d'assainissement."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour le paludisme ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vivre dans des zones endémiques, absence de protection contre les moustiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour la tuberculose ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Conditions de vie précaires, immunodépression et contact avec des malades."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour le choléra ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Accès limité à l'eau potable et à l'assainissement, ainsi que la consommation d'aliments contaminés."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour le VIH ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Relations sexuelles non protégées, partage de seringues et absence de dépistage."
}
}
]
}
]
}
National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam; School of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Viet Nam.
School of Biomedical Sciences, The University of Western Australia, Crawley, WA, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, WA, Australia; PathWest Laboratory Medicine, Department of Microbiology, Nedlands, WA, Australia. Electronic address: thomas.riley@uwa.edu.au.
Division of Cancer Control and Population Sciences, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Second-generation direct-acting antivirals (DAAs) have shown high efficacy in the treatment of chronic hepatitis C virus (HCV) infections in clinical trials. This study aimed to estimate the effective...
In this observational cohort study, patients with active HCV infection who commenced DAA treatment between 2015 and 2020 in Navarre, Spain, were studied. Sustained virological response (SVR), defined ...
Of a total 1366 HCV-infected patients that commenced treatment, 19.3% (n = 263) were HIV-coinfected. After the first DAA treatment, SVR was achieved in 96.6% (n = 1320/1366) of patients and in 97.7% (...
With DAAs, SVR was achieved in all patients with active HCV infection who completed follow-up, and a second course of treatment was only necessary in a small proportion of patients. Adherence to treat...
It is possible that adult ED patients consider their hepatitis C virus (HCV) risk factor history when deciding whether to accept HCV screening. To help address this question, we examined whether self-...
This study was conducted among adult patients ≥18 years old participating in a universal, ED-based HCV screening programme in New York City between 22 January 2019 and 9 April 2020. Participants were ...
Of the 4658 ED patients surveyed, 2846 (61%) accepted and 1812 (39%) declined HCV screening. Among these participants, 38% reported at least one HCV risk factor, most commonly injection drug use. Self...
HCV risk factors were self-reported by more than one-third of ED patients but were not more commonly present among those who accepted HCV screening....
Hepatitis B and hepatitis C are a global burden and underscore the impact of preventable acute and chronic diseases on personal as well as population level health. Caring for pediatric patients with h...
The war invasion of Ukraine in February 2022 led to mass migration. By January 3, 2023, nearly a million people sought refuge in Poland. The Polish Act on Assistance to Ukrainian Citizens provided com...
This paper aims to summarize the epidemiological situation of HCV infections in Poland in 2022, a year characterized by dual crises....
Epidemiological surveillance case-based data on HCV for 2022, diagnosis rates from bulletins for the years 2014-2022, and the number of deaths for 2022 from Statistics Poland were compared with previo...
In 2022, the rate of new HCV diagnoses rose to 6.68 per 100,000, totaling 2,528 cases (a 46% increase from the previous year). Polish nationals accounted for 87% of cases. Gender distribution was equa...
Expanding the availability and accessibility of testing is essential, particularly addressing the needs of key populations, including non-Polish speakers. The strategy for HCV elimination should encom...
It is unknown whether hepatitis C virus (HCV)-cured people with HIV (PWH) without cirrhosis reached the same mortality risk as HCV-uninfected PWH. We aimed to compare mortality in PWH cured of HCV by ...
Nationwide hospital cohort....
HIV-controlled participants without cirrhosis and HCV-cured by DAAs started between September 2013 and September 2020, were matched on age (±5 years), sex, HIV transmission group, AIDS status, and bod...
The analysis included 3961 HCV-cured PWH (G1) and 33 872 HCV-uninfected PWH (G2). Median follow-up was 3.7 years in G1 [interquartile range (IQR): 2.0-4.6], and 3.3 years (IQR: 1.7-4.4) in G2. Median ...
Despite HCV cure and HIV viral suppression, after controlling on factors related to mortality, DAA-cured PWH without cirrhosis remain at higher risk of all-cause mortality than people with HIV monoinf...
High costs of direct-acting antivirals (DAAs) have led to their restricted access for patients with hepatitis C virus (HCV)....
The aim was to assess how HCV treatment access and predictors of HCV treatment changed in the post-DAA period compared with pre-DAA period....
A retrospective cohort study using Arizona Medicaid data was conducted for patients with HCV to compare treatment initiation rates between pre-DAA (January 2008-October 2013) and post-DAA (November 20...
Twenty-four thousand and ninety and 28,756 patients during the pre-DAA and post-DAA periods were identified. Overall, 12.6% were treated in the post-DAA period compared with 7.8% in the pre-DAA period...
Although treatment initiation increased and disparities for Black beneficiaries compared with White beneficiaries attenuated in the post-DAA period, only 13% of Arizona Medicaid patients with HCV rece...
Although anti-hepatitis C virus (HCV) assay is widely used to screen for HCV infection, it has a high false-positive (FP) rate in low-risk populations. We investigated the accuracy of anti-HCV signal-...
We retrospectively analyzed 77,571 patients with anti-HCV results. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic accuracy of anti-HCV S/CO ratio in ...
Overall, 1,126 patients tested anti-HCV positive; 34.7% of patients were FP based on HCV RNA and/or recombinant immunoblot assay (RIBA) results. The age and sex-adjusted anti-HCV prevalence was 1.22%....
The anti-HCV S/CO ratio is highly accurate for discriminating TP from FP HCV infection and should be considered when diagnosing HCV infections....
Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to...
We conducted a qualitative study using focus groups with 23 adults aged 18 years and over who completed DAA treatment or were about to begin such treatment at the time of the study. Participants were ...
Following analysis and interpretation, we generated five theoretically-informed themes characterizing the experiences of individuals accessing DAAs: "being 'worthy' of the cure", "spatially enacted st...
Despite the availability of curative therapies, access to such treatment for people who inject drugs is limited by stigma enacted in and structured within healthcare encounters. Developing novel, low-...
The country of Georgia initiated its hepatitis C virus (HCV) elimination program in 2015, at which point a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and ...
The serosurvey used a stratified, multistage cluster design with systematic sampling to include adults and children (aged 5-17 years) providing consent (or assent with parental consent). Blood samples...
Overall, 7237 adults and 1473 children were surveyed. Among adults, the prevalence of anti-HCV was 6.8% (95% CI, 5.9-7.7). The HCV RNA prevalence was 1.8% (95% CI, 1.3-2.4), representing a 67% reducti...
These results demonstrate substantial progress made in Georgia since 2015. These findings can inform strategies to meet HCV elimination targets....
There are limited data regarding heart transplantation in the setting of hepatitis C virus (HCV) infection in either recipients or donors, as the practice was infrequent, given concerns of worse post-...